Welcome to our dedicated page for RDSMY news (Ticker: RDSMY), a resource for investors and traders seeking the latest updates and insights on RDSMY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RDSMY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RDSMY's position in the market.
Amyris, Inc. (Nasdaq: AMRS) has closed a significant agreement with DSM Nutritional Products Ltd. for exclusive rights to supply its flavor and fragrance ingredients, valued at over $500 million. This amount includes an upfront payment, earn-out payments over three years, and a 15-year manufacturing agreement. The collaboration aims to enhance the development of clean, sustainable chemistry in the industry. Amyris expects this transaction and its first-quarter performance to contribute nearly half of its total anticipated revenue for 2021.
